Table 1: Potential drug classes for therapy in PIH/placental dysfunction.
| Variables | NG group n = 58 | CR group n = 60 | EH group n = 50 | CH group n = 54 | p-value |
| Age (years) | 53.2 ± 10 | 54.1 ± 9.5 | 50.6 ± 12.1 | 54.6 ± 7.9 | 0.181 |
| Sex (male), n(%) | 31 (%53.4) | 33 (%55) | 24 (%48) | 24 (%44.4) | 0.658 |
| Smoking, n (%) | 17 (%29.3) | 19 (%31.7) | 21 (%42.6) | 22 (%40) | 0.404 |
| BMI (kg/m2) | 27.3 ± 2.3 | 27.1 ± 2.3 | 26.8 ± 2.1 | 27.1 ± 2.4 | 0.560 |
| DBP (mmHg) | 83.6 ± 8.5a | 86.1 ± 10.5aa | 90.0 ± 9.1 | 91.4 ± 9.8 | < 0.001 |
| SBP (mmHg) | 142.3 ± 9.6b | 147.2 ± 14.0bb | 154.0 ± 11.3 | 157.5 ± 16.4 | < 0.001 |
| EF (%) | 60.8 ± 4.8c | 61.1 ± 3.9cc | 58.5 ± 5.2 | 57.9 ± 4.6 | < 0.001 |
| LVEDD (cm) | 4.6 ± 0.3d | 4.4 ± 0.3dd | 5.1 ± 0.3ddd | 4.8 ± 0.2 | < 0.001 |
| LVESD (cm) | 3.1 ± 0.2e | 3.0 ± 0.2ee | 3.3 ± 0.3 | 3.2 ± 0.3 | < 0.001 |
| IVS (cm) | 1.00 ± 0.10f | 1.11 ± 0.12ff | 1.17 ± 0.7fff | 1.23 ± 0.13 | < 0.001 |
| PW (cm) | 0.90 ± 0.10f | 1.04 ± 0.11g | 1.05 ± 0.50ddd | 1.17 ± 0.14 | < 0.001 |
| LAD (cm) | 3.3 ± 0.3h | 3.4 ± 0.3hh | 3.7 ± 0.3 | 3.6 ± 0.4 | < 0.001 |
| RWT (g/m2) | 0.38 ± 0.02i | 0.47 ± 0.05hh | 0.40 ± 0.02ddd | 0.49 ± 0.06 | < 0.001 |
| LV mass (g) | 152.8 ± 38.1b | 166.8 ± 34.8k | 225.5 ± 32.5 | 223.2 ± 43.3 | < 0.001 |
| LVMI (g/m2) | 79.9 ± 18.2b | 85.9 ± 16.1k | 121.5 ± 17.1 | 126.7 ± 29.7 | < 0.001 |
| E/A | 1.1 ± 0.5m | 0.8 ± 0.3 | 0.9 ± 0.4 | 0.9 ± 04 | 0.002 |
| E/Em | 8.0 ± 2.1n | 8.6 ± 3.0 | 9.2 ± 2.2 | 10.3 ± 3.9 | 0.001 |
ap = 0.004 between NG and EH groups, p < 0.001 between NG and CH groups; aap = 0.020 between CR and CH groups; bp < 0.001 between NG, EH and CH groups; bbp = 0.030 between CR and EH groups, p = 0.003 between CR and EH groups; cp = 0.007 between NG and CH groups; ccp = 0.019 between CR and EH groups, p = 0.002 between CR and CH groups; dp = 0.002 between NG and CR groups, p < 0.001 between NG and EH groups, p = 0.021 between NG and CH groups; ddp = 0.002 between NG and CR groups, p < 0.001 between CR, EH and CH groups;
dddp < 0.001 between EH and CH groups; ep = 0.012 between NG and EH groups; eep < 0.001 between CR and EH goups, p = 0.005 between CR and CH groups; fp < 0.001 between NG, CR, EH and CH groups; ffp = 0.009 between CR and EH groups, p < 0.001 between CR and CH goups; fffp = 0.068 between EH and CH groups; gp < 0.001 between CR and CH groups; hp < 0.001 between NG and EH groups, p = 0.014 between NG and CH groups; hhp < 0.001 between CR and EH groups; ip < 0.001 between NG, CR and CH groups, p = 0.004 between NG and EH goups; kp < 0.001 between CR, EH and CH groups; mp = 0.003 between NG and CR groups, p = 0.008 between NG and CH groups; np = 0.044 between NG and EH groups, p = 0.002 between NG and CH groups.
NG: Normal Geometry; CR: Concentric Remodelling; EH: Eccentric Hypertrophy; CH: Concentric Hypertrophy; BMI: Body Mass İndex; DBP: Diastolic Blood Pressure; SBP: Systolic Blood Pressure; EF: Ejection Fraction; LVEDD: Left Ventricular End-Diastolic Dimension; LVESD: Left Ventricular End-Systolic Dimension ; IVS: İnterventricular Septal Thickness; PW: Posterior Wall Thickness; LAD: Left Atrial Diameter; RWT: Relative Wall Thickness; LV: Left Ventricular; LVMI: Left Ventricular Mass İndex; E/A: Peak Velocity of Early Diastolic Flow/Peak Velocity of Late Diastolic Flow; E/Em: Peak Velocity Of Early Diastolic Flow Across Mitral Valve/Myocardial Peak Velocity of Early Diastole.